Drugs / [1-13C]Pyruvate
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02648009 | Apr 2016 → Apr 2027 expected | hypertensive disorder | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05396118 | May 2022 → Aug 2024 | breast cancer, lymphoma, neuroendocrine carcinoma, sarcoma | Rigshospitalet, Denmark | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [1-13C]pyruvate | “Four healthy subjects underwent conventional proton cardiac magnetic resonance imaging followed by 13C imaging and spectroscopic acquisition immediately after intravenous...” PMID 27635086 ↗ Sep 2016 |
| Modality | Diagnostic / imaging agent | “DNP-dissolution results in an intravenous contrast agent that is "hyperpolarized", producing a magnetic signal that is enhanced by up to 100,000 fold.” NCT02648009 ↗ |
| Route | Intravenous | “A 0.1 mmol/kg dose (approximately 20 mL) of this solution will be injected through an intravenous line.” NCT02648009 ↗ |